Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 16/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP4 | P49662 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13910797 | 0.93 | CHRM5 (0.56) | CHRM5 | |
| SCHEMBL13627972 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HPGDHTTCASP1CASP3 | |
| SCHEMBL13627951 | 0.82 | ALDH1A1 (0.72) | ALDH1A1HPGDHTTCASP1CASP3 | |
| SCHEMBL13628004 | 0.81 | CHRM5 (0.74) | CHRM5 | |
| SCHEMBL13627915 | 0.80 | CASP1 (0.56) | ALDH1A1HPGDHTTCASP1CASP3 | |
| SCHEMBL13628006 | 0.80 | CHRM5 (0.63) | CHRM5 | |
| SCHEMBL13627910 | 0.78 | CASP1 (0.72) | ALDH1A1HPGDHTTCASP1CASP3 | |
| SCHEMBL13627913 | 0.78 | CASP1 (0.56) | ALDH1A1HPGDHTTCASP1CASP3 | |
| SCHEMBL13627911 | 0.74 | CASP3 (0.56) | CHRM5ALDH1A1HPGDHTTCASP1 | |
| SCHEMBL13627887 | 0.73 | MAPT (0.66) | ALDH1A1HPGDHTTCASP1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | MAP3K1, JUN, MAP3K7 | CHRM5 4815/4885ALDH1A1 4310/4885HPGD 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.